DEA Revokes California MD's Drug Handling License
Published Date: 9/30/2025
Notice
Summary
Dr. David Payne from California lost his DEA license to handle controlled substances because he’s no longer allowed to prescribe or participate in federal health programs. He didn’t ask for a hearing, so the DEA made the decision final. This means he can’t legally prescribe or manage controlled drugs starting now, impacting his medical practice and federal program involvement.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for David Payne
The Drug Enforcement Administration revoked David Payne, M.D.'s DEA Certificate of Registration No. BP3113963 and denied any pending applications to renew, modify, or obtain additional registration in California. The Order takes effect October 30, 2025, and follows findings that his California medical license is suspended.
14-Year Federal Health Program Exclusion
The record shows David Payne, M.D. was mandatorily excluded from participation in Medicare, Medicaid, and all Federal health care programs effective May 20, 2024, for a period of fourteen years. That exclusion is an independent basis the DEA relied on to revoke his registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-19053, Self-Regulatory Organizations; Financial Industry Regulatory Authority, Inc.; Notice of Partial Amendment No. 1 to Proposed Rule Change To Amend the FINRA Capital Acquisition Broker (“CAB”) Rules
FINRA wants to update its Capital Acquisition Broker (CAB) rules to let brokers work with more types of investors and handle private securities deals more flexibly. These changes affect brokers, investors, and companies selling unregistered securities, aiming to make deals smoother and clearer. The SEC is reviewing the updates, with decisions expected soon, but no immediate money changes are announced.
Next: 2025-19056, Self-Regulatory Organizations; Fixed Income Clearing Corporation; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend GSD Rule 42 (Suspension of Rules) and MBSD Rule 33 (Suspension of Rules in Emergency Circumstances)
The Fixed Income Clearing Corporation (FICC) is updating its emergency rules to make it clearer when and how they can pause certain operations during unusual situations. This change affects firms using FICC’s Government Securities and Mortgage-Backed Securities services, helping everyone stay safe and sound when things get tricky. The new rules took effect right away on September 25, 2025, with no extra costs involved.